Skip to main content

Table 5 Summary principle component analysis

From: Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines

A
Component-HC
1 2 3 4 5 6 7 8
37.7% 13.4% 11.1% 7.5% 6.7% 5.3% 3.7% 3.2%
IL-13 CCL4 CCL3 IL-6R TIMP1 CCL19 TNFα IL-23
IL-5 CCL2 IL-10 IL-18 IL-6 CCL5* IL-1RA CCL18
IL-22 IL-1α ICAM1 Adiponectin Cathepsin-S IL-1β * IL-4  
CCL19 IL-8 IL-27 IL-1β   MIF   
VEGF CCL3 IL-25      
CCL22 CCL5 IL-21      
CXCL9   IFNα      
VCAM1   IL-6R      
IL-7        
HGF        
IL-23        
mTLE Δ mTLE Δ mTLE + HS Δ ND ND mTLE + HS Δ ND ND
control control -HS & control    & control   
B        
Component-CX        
1 2 3 4 5 6 7 8
40.1% 10% 8.4% 8% 5.8% 5% 4% 3.3%
IL-5 IL-18 CCL2 Adiponectin CXCL9 TIMP1 IL-1β IL-25
VEGF IL-6R CCL4 ICAM1 CCL5 CXCL8.IL-8 IL-6 IL-21
VCAM1 MIF Adiponectin Cathepsin-S HGF IL-1α IFNα IL-4
CCL3 IL-1β CXCL8.IL-8 CCL18   TNFα IL-23 IL-10
CCL19 TNFα     IL-4   
IL-1RA        
IL-27        
IL-22        
IL-13        
IL-25        
CCL22        
IL-7        
CXCL9        
IL-1α        
IL-23        
TNFα        
mTLE Δ ND ND ND mTLE Δ mTLE + HS Δ ND mTLE + HS Δ
control     control & control   -HS & control
  1. PCA identified 8 components in HC(A) and CX (B) that explain 88.5% (HC) and 84% (CX) of the variance in all the samples. The contribution of each component to the variance is given as percentage. Inflammatory mediators are listed in order of factor loading. Under each component list significant differences in this component between patient groups is indicated (delta). ND = no difference detected between component scores among the three patient groups.